Medtronic MDT Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Cardiovascular | $13.98B+12.0% | $12.48B+5.5% | $11.83B+2.7% | $11.52B+1.4% | |
| Diabetes | $3.11B+13.0% | $2.76B+10.8% | $2.49B+9.9% | $2.26B-3.3% | |
| Medical Surgical | $8.81B+4.8% | $8.41B-0.1% | $8.42B+5.4% | $7.99B-5.7% | |
| Neuroscience | $10.29B+4.5% | $9.85B+4.7% | $9.41B+5.0% | $8.96B+2.0% | |
| Other Operating Segments | $135M-1.5% | $137M-38.0% | $221M— | —— | |
| Reportable segment operating profit by Business | |||||
| Cardiovascular | $3.67B+9.8% | $3.34B+1.4% | $3.3B-27.1% | $4.52B-1.6% | |
| Medical Surgical | $2.13B+2.8% | $2.07B-11.2% | $2.33B-23.5% | $3.05B-17.6% | |
| Neuroscience | $3.06B+1.0% | $3.03B+6.3% | $2.85B-23.2% | $3.71B-3.7% | |
| Other segment items by Business | |||||
| Cardiovascular | -$47M-14.6% | -$41M-46.4% | -$28M+9.7% | -$31M— | |
| Medical Surgical | $14M-22.2% | $18M+100% | $9M+190% | -$10M— | |
| Neuroscience | $36M+16.1% | $31M+3.3% | $30M-59.5% | $74M— | |
| Cost of products sold, excluding amortization of intangible assets by Business | |||||
| Cardiovascular | $4.69B+13.5% | $4.14B+6.3% | $3.89B+9.2% | $3.56B— | |
| Medical Surgical | $3.48B+6.8% | $3.26B+2.7% | $3.17B+10.8% | $2.86B— | |
| Neuroscience | $3.15B+8.8% | $2.9B+4.9% | $2.76B+14.5% | $2.41B— | |
| Selling, general, and administrative expense by Business | |||||
| Cardiovascular | $4.52B+12.4% | $4.02B+3.1% | $3.9B+47.0% | $2.65B— | |
| Medical Surgical | $2.51B+4.7% | $2.4B-0.1% | $2.4B+54.9% | $1.55B— | |
| Neuroscience | $3.42B+4.5% | $3.28B+3.3% | $3.17B+44.8% | $2.19B— | |
| Currency translation and other by Business | |||||
| Other Operating Segments | $0-100% | $1M— | —— | —— | |
| Depreciation by Business | |||||
| Cardiovascular | $253M+12.4% | $225M+13.1% | $199M-4.8% | $209M-0.5% | |
| Medical Surgical | $225M+10.3% | $204M+5.2% | $194M-4.4% | $203M+9.1% | |
| Neuroscience | $321M+14.2% | $281M+11.5% | $252M-5.6% | $267M+0.8% | |
| Research and development expense by Business | |||||
| Cardiovascular | $1.14B+11.4% | $1.02B+2.9% | $991M+21.6% | $815M— | |
| Medical Surgical | $687M+3.2% | $666M+3.1% | $646M+19.0% | $543M— | |
| Neuroscience | $616M+0.7% | $612M-1.9% | $624M+8.9% | $573M— | |
| Net Sales by Geography | |||||
| Ireland | $143M+22.2% | $117M+4.5% | $112M+13.1% | $99M-2.9% | |
| Rest of world | $18.12B+11.5% | $16.25B+3.6% | $15.69B+6.3% | $14.76B-4.5% | |
| United States | $18.1B+5.4% | $17.17B+3.7% | $16.56B+1.2% | $16.37B+1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medtronic break its business down?
- Medtronic (MDT) reports net sales by business across 6 parts — Cardiovascular, Diabetes, Medical Surgical, Neuroscience and Other operating segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Medtronic's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medtronic's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
